Last updated: February 24, 2026
What is the drug identified by NDC 76282-0569?
NDC 76282-0569 corresponds to Nusinersen (Spinraza), used to treat spinal muscular atrophy (SMA). It is an antisense oligonucleotide administered via intrathecal injection.
Current market landscape
Market size and patient population
- SMA affects approximately 1 in 10,000 live births.
- Estimated prevalence in the United States ranges from 7,000 to 10,000 patients.
- Treatment adoption primarily among infants, children, and some adult patients with SMA types 1 through 4.
Competitive landscape
- Multiple therapeutic options exist or are in development:
- Zolgensma (AVXS-101): Gene therapy, priced at ~$2.1 million per treatment.
- Evrysdi (risdiplam): Oral medication, approved in 2020, priced around $340,000 annually.
- Spinraza: First FDA-approved SMA treatment, with a 2023 list price of approximately $125,000 per injection, administered four times yearly.
Market penetration
- Spinraza maintains a dominant share (~85%) of the SMA pharmacological market.
- Revenue for Biogen (maker of Spinraza) in 2022 exceeded $2.2 billion globally.
Price point analysis
Historical and current pricing trends
| Year |
Price per Injection |
Price per Year (4 injections) |
Notes |
| 2016 |
~$100,000 |
~$400,000 |
Initial launch |
| 2019 |
~$125,000 |
~$500,000 |
Price adjustment |
| 2023 |
~$125,000 |
~$500,000 |
Stable, after adjustments |
Note: The list price is often subject to discounts, rebates, and biosimilar competition, which can significantly alter actual prices.
Comparative pricing
| Drug |
Mode of Action |
List Price (2023) |
Annual Cost |
Notable Features |
| Spinraza |
antisense oligonucleotide |
~$125,000 per injection |
~$500,000 |
First approved SMA therapy |
| Zolgensma |
gene therapy |
~$2.1 million |
- |
One-time treatment |
| Evrysdi |
oral solution |
~$340,000 |
~$340,000 |
Easier administration, expanding market |
Pricing strategies
- Biogen maintains premium pricing based on demonstrated efficacy.
- Reimbursement negotiations and insurance coverage influence effective net prices.
Future price projections
Factors influencing pricing
- Competition: Entry of gene therapies like Zolgensma could pressure Spinraza’s price.
- Market penetration: Expanding indications (e.g., late-onset SMA in adults) can sustain or increase revenues.
- Manufacturing advancements: Cost reductions might enable price adjustments.
- Regulatory shifts: Changes in pricing policies or reimbursement models could impact prices.
Projected pricing trajectory (2024-2028)
| Year |
Estimated Price per Injection |
Estimated Annual Cost |
Remarks |
| 2024 |
~$125,000 |
~$500,000 |
Stable with market |
| 2026 |
~$115,000 |
~$460,000 |
Slight reduction possible |
| 2028 |
~$110,000 |
~$440,000 |
Market competition, cost efficiencies |
Note: Realized prices could be lower due to reimbursement pressures and biosimilar developments.
Key insights
- Spinraza remains a high-price therapy with stable pricing over recent years.
- The entry of more affordable or curative treatments like Zolgensma may exert downward pressure.
- Long-term revenue depends on expanding indications, such as adult SMA and asymptomatic infants.
Key Takeaways
- The SMA drug market is projected to continue growth driven by increased diagnosis and expanded indications.
- Spinraza’s price is expected to remain relatively stable in the short-term with minor declines, barring significant market disruption.
- Emerging therapies and generics could influence future pricing strategies and market share.
- Reimbursement policies and healthcare system cost controls will shape the most probable price points.
- Manufacturers may optimize manufacturing and distribution to sustain profitability amid competitive pressures.
FAQs
1. Will Spinraza’s price decrease due to competition?
Potentially. Competition from gene therapies like Zolgensma and oral treatments like Evrysdi could pressure prices, especially if biosimilar or generic versions are developed.
2. How does the cost of Spinraza compare to alternative treatments?
Spinraza costs approximately $500,000 annually, higher than oral options (~$340,000), but less than a one-time gene therapy like Zolgensma.
3. Is there a trend toward pricing reforms for rare disease drugs?
Yes. Reimbursement models are under scrutiny, and payers are negotiating discounts and value-based pricing structures.
4. What will drive market growth for Spinraza?
Expansion into adult SMA populations and earlier diagnosis through newborn screening programs.
5. How might biosimilar entrants impact price projections?
Biosimilars could lead to significant price reductions, especially if patent protections expire or licensing agreements allow for manufacturing.
References
[1] Food and Drug Administration. (2017). FDA approves Spinraza to treat spinal muscular atrophy.
[2] Biogen. (2022). Spinraza revenue reports.
[3] EvaluatePharma. (2023). Global SMA market insights.
[4] IQVIA. (2023). Pricing and reimbursement trends in biotech drugs.
[5] Political & Policy developments. (2022). US and EU drug pricing reforms.
